Abstract. Our previous study demonstrated that diabetes increases in-stent restenosis following rapamycin-eluting stent placement, which was defined as rapamycin resistance. However, the underlying mechanisms of rapamycin resistance remain to be determined. In the present study, male apolipoprotein E-deficient (ApoE -/-) mice were randomly divided into control and diabetic groups. Diabetes was induced by injecting streptozocin (STZ). The hyperglycemic state, defined as a fasting plasma glucose level >13 mmol/l, was maintained for 8 weeks. At the end of the administration, the plasma levels of triglycerides (TG) and total cholesterol (TC) were significantly elevated in the diabetic group compared with the control mice (all P<0.01). The present study revealed that diabetes increased the atherosclerotic plaque size of the aortic root (P<0.01) and the content of vascular smooth muscle cells (VSMCs) in the atherosclerotic lesion (P<0.01). Furthermore, the protein expression and phosphorylation of mammalian target of rapamycin (mTOR), 4E-binding protein 1 and ribosomal S6 kinase 1 (P<0.01) were significantly decreased in the diabetic mice compared with the control group. The decrease in the expression and phosphorylation of mTOR and its downstream kinases may be one of the molecular mechanisms underlying rapamycin resistance.
Introduction
Arteriosclerotic coronary disease is now the leading cause of mortality worldwide (1) . Percutaneous transluminal coronary angioplasty has become the most common strategy for the treatment of severe coronary artery disease. Restenosis is a potential limitation of percutaneous coronary angioplasty. Although intracoronary stents reduce the incidence of restenosis following percutaneous coronary intervention (PCI), in-stent stenosis remains an important issue (2) . Restenosis following PCI is predominantly caused by the proliferation of vascular smooth muscle cells (VSMCs) (3) . The introduction of drug eluting stents (DES) has significantly decreased the rates of restenosis by inhibiting the accumulation and proliferation of VSMCs. Nevertheless, in-stent restenosis following PCI remains a challenging clinical problem despite the use of DES (4) . It has been reported that the rate of restenosis remains at 7-16% in diabetic patients who have received DES (5) . Our previous study demonstrated that diabetes increases restenosis following rapamycin-eluting stent placement (6) , indicating that diabetes remains an important predictor for restenosis in the DES era. When rapamycin becomes less effective at preventing in-stent restenosis, this condition is termed 'rapamycin resistance' (6) . However, the underlying mechanisms of rapamycin resistance remain to be determined.
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that is important in mediating the proliferation of VSMCs (7) . The best characterized downstream targets of mTOR are 4E-binding protein 1 (4EBP1) and ribosomal S6 kinase 1 (S6K1) (8) . The activation of mTOR leads to the phosphorylation of 4EBP1 and S6K1, leading to the promotion of the initiation and elongation phases of mRNA translation and consequently the stimulation of VSMC proliferation. Rapamycin is a specific inhibitor of mTOR and suppresses the proliferation of VSMCs through inhibiting the mTOR-mediated proliferative signaling pathway (9) . Therefore, the expressional and functional status of mTOR may affect the antiproliferative effect of rapamycin.
The present study hypothesized that diabetes may affect the expression of mTOR and its downstream kinases, attenuate the action of rapamycin and cause the clinical phenomena of rapamycin resistance. As a proof-of-concept study, the present study assessed how diabetes affected the growth of atherosclerotic lesions and mTOR expression in atherosclerotic plaques of apolipoprotein E-deficient (ApoE Animal model. The mice were randomly divided into two groups: The control group (n=8) and the diabetes group (n=8). The mice in the diabetic group were intraperitoneally injected with 55 mg/kg streptozocin (STZ; in 0.05 mol/l citrate buffer; pH 4.5; Sigma, St. Louis, MO, USA) for five consecutive days. The mice in the control group were injected with an equal volume of citrate buffer. Fasting tail-blood glucose concentration (FBG) level was measured using a glucose test strip (Roche Diagnostics GmbH, Mannheim, Germany). Animals were considered to be diabetic if their FBG level was >13 mmol/l. The FBG levels of all mice were monitored at baseline and at weeks 1, 3 and 8 after injection of STZ.
Materials and methods

Animal
Serum lipids. Fasting blood samples were obtained at the end of the experiments. The triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels were measured by colorimetric assays using a commercially available kit (Jiancheng Bioengineering Institute, Nanjing, China) according to our previous study (10) .
Atherosclerosis analysis. Atherosclerotic lesions in the aortic roots were examined in cross sections of the aortic origin according to a previous study (11) . The sections (5 µm) were stained with hematoxylin and eosin, and images were captured on an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan). The atherosclerotic lesion area was quantified using Nikon NIS-Elements Research software (Nikon, Tokyo, Japan).
Immunohistochemistry. The protein expression of smooth muscle (SM) α-actin and mTOR in atherosclerotic plaques was detected by immunohistochemical staining (12) . Aortic roots were fixed in 4% paraformaldehyde for 12 h, embedded in paraffin and then cut into sections (5 µm). The sections were incubated with anti-SM α-actin (BM002) and mTOR (Ab-2448) antibodies (diluted 1:50). Specific binding was detected using complexes of biotinylated goat anti-rabbit IgG secondary antibody and horseradish peroxidase using ABC kits (Boster Bioengineering Co., Wuhan, China). The antigen-antibody complex was subsequently visualized with DAB solution (Boster Bioengineering Co.). The sections were viewed under a light microscope. For the detection of positive staining, the portion of the color spectrum representing the positive signal for each stain was defined using the color cube-based method in Image-Pro plus 6.0 (Media Cybernetics, Inc., Bethesda, MD, USA). This color definition was then applied uniformly to all digitized images for that stain to determine the total positive area within the plaque and this positive area measurement was then normalized to the total area of the plaque. Additionally, the mean light density of the positive area was calculated.
Western blot analysis. Protein lysates were obtained by homogenizing aortic tissues with lysis buffer containing 1% Triton X-100, 150 mmol/l NaCl, 1 mmol/l EDTA, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l β-glycerophosphate, 1 mmol/l Na 3 VO 4 , 1 µg/ml leupeptin, 1 µg/ml aprotinin and 20 mmol/l Tris (pH 7.5) (13). The protein concentration was determined using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA). Equal quantities of protein from the heart extracts were separated by SDS-PAGE (12%). The samples were then electroblotted onto a nitrocellulose membrane (Boehringer Mannheim Corporation, Indianapolis, IN, USA) and probed with antibodies against mTOR (Ab-2448, rabbit polyclonal), phospho-mTOR-Ser2448 (p-mTOR; Ab-11221, rabbit polyclonal), phospho-4EBP1-Ser 65/Thr 70 (p-4EBP1; sc-12884, goat polyclonal), phospho-S6K1 (p-S6K1; eptomics-1175-1, rabbit monoclonal) and glyceraldehyde 3 phosphate dehydrogenase (GAPDH; sc-365062, mouse monoclonal) overnight. Following washing, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (1:1,000 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and bound antibody was visualized using a colored reaction. The relative band densities were quantified by densitometry using the Multi-Analyst software package (Bio-Rad). The equal loading of protein was confirmed by measuring GAPDH expression.
Statistical analysis. Continuous data are presented as the mean ± standard error of the mean. Comparisons between the two groups were determined by the independent samples t-test (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Characteristics of diabetic ApoE
-/-mice. The body weight of control ApoE -/-mice significantly increased 8 weeks after the start of the experiment. However, the body weight of diabetic ApoE -/-mice decreased marginally following STZ administration and was significantly lower than that of the control mice at the end of the experiment (P<0.01; Fig. 1A) . No significant changes in the fasting blood glucose level in the control mice were observed. However, the fasting glucose concentration of diabetic mice increased to a level >20 mmol/l 3 weeks after STZ injection and maintained the hyperglycemic state until the end of the experiment (Fig. 1B) . The plasma TG, TC, LDL-C and HDL-C concentrations in the diabetic mice were significantly higher than those of the control mice ( Fig. 1C ; all P<0.01).
Diabetes enhances atherosclerotic lesions. At week 8 after STZ administration, the atherosclerotic plaque area of the aortic root was significantly increased in diabetic mice compared with the control group (P<0.01; Fig. 2A and B) .
Diabetes increases VSMC content in atherosclerotic plaques.
The proliferation of VSMCs in the atherosclerotic plaque and the vascular wall contributes to the development of restenosis. The VSMCs in atherosclerotic plaques were detected by immunohistochemistry staining. The content of VSMCs in diabetic mice expressed as the positive area or mean density was significantly higher than that in the control group (P<0.01; Fig 3A, B and C) .
Diabetes inhibits the mTOR signaling pathway. The mTOR signaling pathway and its downstream kinases have been viewed as the major regulators of the proliferation of VSMCs. The protein expression of mTOR in atherosclerotic plaques from diabetic mice was significantly decreased compared with that of the control animals (P<0.05; Fig. 4A and C) . The protein expression of mTOR, p-mTOR and its major downstream kinases p-4EBP1 and p-S6K1 in aortic tissue were significantly downregulated in the diabetic mice compared with the control group (all P<0.01; Fig. 4B and D) .
Discussion
Our previous clinical follow-up study demonstrated that diabetes remains an independent risk factor for restenosis following DES in coronary arteries (6) . There is also evidence that the efficacy of DES in the diabetic state varied with the type of stent (everolimus eluting stents and sirolimus eluting stents > paclitaxel eluting stents and zotarolimus eluting stents) (14) . These results suggest that diabetic patients have a distinct expressional model of the target of eluted drug. Therefore, the present study hypothesized that rapamycin resistance in diabetes is attributed to alterations in the expression of the rapamycin target mTOR and its downstream signaling pathway. The present study provides compelling evidence supporting the concept that diabetes not only significantly enhances the growth of atherosclerotic plaques and the proliferation of VSMCs, but also downregulates the expression of mTOR, 4EBP1 and S6K1. Therefore, alterations in the expression of the mTOR signaling pathway may mediate the clinical phenomenon of rapamycin resistance.
Although the macrophage-derived foam cell is important in the development of atherosclerosis, the migration and proliferation of VSMCs in the arterial intima are also key events in the formation of atherosclerotic lesions (15) . The proliferation of VSMCs is not only involved in the formation of plaques, but also contributes to the process of in-stent restenosis. Growth factors, including platelet-derived growth factor, basic fibroblast growth factor and insulin-like growth factor-1, stimulate VSMCs to enter the cell cycle and proliferate (16) . Currently, DESs delivering rapamycin, rapamycin analogues or paclitaxel were used to prevent in-stent restenosis through inhibiting the proliferation of VSMCs (17) . The specific target of rapamycin is mTOR. The mTOR pathway regulates VSMC growth through effectors, including 4EBP1 and S6K1. Diabetic patients remain at an increased risk of developing in-stent restenosis despite the use of rapamycin eluting stents, which was observed in the present study and in other studies (6, 18) . The phenomenon of rapamycin resistance may result from two distinct issues. One is that the mTOR signaling pathway is impaired in diabetes and the other is that the mTOR signaling pathway is over-activated by diabetes. A previous in vitro experiment demonstrated that increased leptin levels, which mimicked hyperleptinemia in diabetes and metabolic syndrome, may activate the mTOR signaling pathway in primary cultured VSMCs (19) , suggesting that a higher dose of rapamycin may be more effective in limiting in-stent restenosis in the setting of hyperleptinemia. However, the present in vivo study demonstrated that the mTOR signaling pathway is downregulated in the setting of hyperglycemia. This result suggests that a higher dose of rapamycin is not an effective therapeutic strategy to limit in-stent restenosis.
Based on the current available evidence, the critical mechanism mediating in-stent restenosis in the setting of diabetes has not been elucidated. As the mTOR signaling pathway has been demonstrated to be inhibited by diabetes, certain other signaling pathways may exhibit compensatory upregulation or activation. The underlying mechanisms controlling the proliferation of VSMCs in the setting of hyperglycemia remain to be revealed in future studies. The in-stent restenosis in diabetes may be resolved by using two or multiple DES.
In conclusion, decreases in the expression and phosphorylation of mTOR and its downstream kinases may be one of the molecular mechanisms underlying rapamycin resistance. Future investigation is required to identify potential targets involved in in-stent restenosis under diabetic conditions.
